Pfizer Inc. and Bayer said on March 14 they would maintain humanitarian supply of medicines to Russia, but would pull back from other non-essential spending in the country.
A therapy mix including Bayer’s Nubeqa drug was shown to significantly prolong the lives of men suffering from metastatic prostate cancer in a clinical study, prompting the company to boost sales estimates for the product.
Germany’s Bayer won fast-track status from U.S. drugs regulators for a new blood thinner designed to prevent certain types of strokes, as the company seeks to follow up on the success of the anticoagulant Xarelto.
The U.S. Commerce Department added 33 Chinese entities to an “unverified list,” requiring U.S. exporters to undergo more procedures before shipping goods to the companies. WuXi Biologics was amongst those on the list, with the United States stating that it was unable to verify the legitimacy and reliability of the company’s use of U.S. exports.
Cellino Biotech announced a completed Series A financing of $80 million led by the impact investment arm of Bayer AG, Leaps by Bayer, 8VC, and Humboldt Fund and includes new investor Felicis Ventures.
Bayer on January 10 struck a partnership deal with Mammoth Biosciences to develop therapeutic tools based on CRISPR/CAS9 gene editing as the German drug maker seeks to widen the company’s cell and gene therapy development efforts.
Older adults taking Bayer AG’s blockbuster blood thinner pill Xarelto for a common type of irregular heart rhythm had significantly higher rates of serious bleeding and stroke compared to those taking rival pill Eliquis, a U.S. study showed.
A California jury found that Bayer’s Roundup weedkiller was not the cause of a woman’s non-Hodgkin’s lymphoma, Bayer said on December 9, delivering the chemical giant a second trial victory over claims the popular herbicide causes cancer.
Seattle-based Mozart Therapeutics closed on a $55 million Series A financing round, led by seed financier ARCH Venture Partners along with Sofinnova Partners. Additional investors were Eli Lilly and Company, MRL Ventures Fund, an early-stage fund run by Merck & Co., Leaps by Bayer, Altitude Life Science Ventures, and Alexandria Venture Investments.
Bayer terminated a vaccine manufacturing partnership under which the company would have helped produce CureVac’s Covid-19 shot, a spokesperson for Bayer told a German newspaper.